<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340057</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1027</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091027</ELocationID><Abstract><AbstractText>We were tasked by Canada's COVID-19 Immunity Task Force to describe severe adverse events (SAEs) associated with emergency department (ED) visits and/or hospitalizations in individuals with immune-mediated inflammatory diseases (IMIDs). At eight Canadian centres, data were collected from adults with rheumatoid arthritis (RA), axial spondyloarthritis (AxS), systemic lupus (SLE), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD). We administered questionnaires, analyzing SAEs experienced within 31 days following SARS-CoV-2 vaccination. About two-thirds (63%) of 1556 participants were female; the mean age was 52.5 years. The BNT162b2 (Pfizer) vaccine was the most common, with mRNA-1273 (Moderna) being second. A total of 49% of participants had IBD, 27.4% had RA, 14.3% had PsA, 5.3% had SpA, and 4% had SLE. Twelve (0.77% of 1556 participants) SAEs leading to an ED visit or hospitalization were self-reported, occurring in 11 participants. SAEs included six (0.39% of 1556 participants) ED visits (including one due to Bell's Palsy 31 days after first vaccination) and six (0.39% of 1556 participants) hospitalizations (including one due to Guillain-Barré syndrome 15 days after the first vaccination). Two SAEs included pericarditis, one involved SLE (considered a serious disease flare), and one involved RA. Thus, in the 31 days after SARS-CoV-2 vaccination in our IMID sample, very few serious adverse events occurred. As SARS-CoV2 continues to be a common cause of death, our findings may help optimize vaccination acceptance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsyruk</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Gilaad G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-2719-0556</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB T2N 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Centre de Recherche ARThrite-UL, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitchon</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larché</LastName><ForeName>Maggie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avina-Zubieta</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arthritis Research Canada and Division of Rheumatology, University of British Columbia, Vancouver, BC V5Y 3P2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boire</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2481-5821</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colmegna</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacaille</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Arthritis Research Canada and Division of Rheumatology, University of British Columbia, Vancouver, BC V5Y 3P2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalonde</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proulx</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Dawn P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boivin</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeBow</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovalova-Wood</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paleczny</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>Linda</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0009-9719-318X</Identifier><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukusa</LastName><ForeName>Luck</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jennifer Lf</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-5501-0017</Identifier><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernatsky</LastName><ForeName>Sasha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9515-2802</Identifier><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>On Behalf Of The Succeed Investigative Team</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2122-HQ-000070</GrantID><Agency>Public Health Agency of Canada</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine safety</Keyword><Keyword MajorTopicYN="N">immune-mediated inflammatory diseases</Keyword><Keyword MajorTopicYN="N">serious adverse events</Keyword></KeywordList><CoiStatement>The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Dr. Boire has received honoraria (none relevant to this work) for speaking or consultancy from Abbvie, BMS, Lilly, Novartis, Pfizer, Samsung BioEpis, and Viatris; multi-centric research grants (none relevant to this work) from Janssen and Pfizer; and unrestricted grant support (none relevant to this work) for local initiatives from BMS, Lilly, and Pfizer. Dr. Chandran has received research grants from AbbVie and has received honoraria from the advisory board and consultations from AbbVie, Amgen, BMS, Eli Lilly, Fresenius Kabi, Janssen, Novartis, and UCB. His spouse is an employee of AstraZeneca. Dr. Fortin participated in advisory boards for Moderna in 2023 that are not related to this work. Dr. Hitchon participated in advisory boards for AstraZeneca (not related to this work) and has received research grants (unrelated to this work) for multi-centric research and from Pfizer (unrelated to this work).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340057</ArticleId><ArticleId IdType="pmc">PMC11436126</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091027</ArticleId><ArticleId IdType="pii">vaccines12091027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. doi: 10.1038/s41586-020-2798-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L., Widdifield J., Rosen C.F., Cook R., Lee K., Alhusayen R., Paterson M.J., Cheng S.Y., Jabbari S., Campbell W., et al. Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study. Arthritis. Care. Res. 2019;71:1084–1091. doi: 10.1002/acr.23743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23743</ArticleId><ArticleId IdType="pubmed">30171803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32448-0</ArticleId><ArticleId IdType="pubmed">29050646</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdifield J., Paterson J.M., Bernatsky S., Tu K., Tomlinson G., Kuriya B., Thorne J.C., Bombardier C. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis. Rheumatol. 2014;66:786–793. doi: 10.1002/art.38306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38306</ArticleId><ArticleId IdType="pubmed">24757131</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenna B., AKennedy N., Mehrkar A., Rowan A., Galloway J., Matthewman J., Mansfield K.E., Bechman K., Yates M., Brown J., et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: A nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4:e490–e506. doi: 10.1016/S2665-9913(22)00098-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00098-4</ArticleId><ArticleId IdType="pmc">PMC9179144</ArticleId><ArticleId IdType="pubmed">35698725</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A., Herauf M., Quan J., Hracs L., Windsor J.W., Sharifi N., Coward S., Caplan L., Gorospe J., Ma C., et al. Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease. Am. J. Gastroenterol. 2023;118:1693–1697. doi: 10.14309/ajg.0000000000002337.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000002337</ArticleId><ArticleId IdType="pmc">PMC10453345</ArticleId><ArticleId IdType="pubmed">37216598</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine Vigilance Working Group &amp; PHAC  Reporting Adverse Events Following Immunization (AEFI) in Canada: User Guide to Completion and Submission of the AEFI Reports. Government of Canada. 2023.  [(accessed on 3 September 2024)].  Available online:  https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/user-guide-completion-submission-aefi-reports.html.</Citation></Reference><Reference><Citation>Yasmin F., Najeeb H., Naeem U., Moeed A., Atif A.R., Asghar M.S., Nimri N., Saleem M., Bandyopadhyay D., Krittanawong C., et al. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun. Inflamm. Dis. 2023;11:e807. doi: 10.1002/iid3.807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.807</ArticleId><ArticleId IdType="pmc">PMC10022421</ArticleId><ArticleId IdType="pubmed">36988252</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraiman J., Erviti J., Jones M., Greenland S., Whelan P., Kaplan R.M., Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022;40:5798–5805. doi: 10.1016/j.vaccine.2022.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.036</ArticleId><ArticleId IdType="pmc">PMC9428332</ArticleId><ArticleId IdType="pubmed">36055877</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels L.E., Ammitzbøll C., Andersen J.B., Vils S.R., Mistegaard C.E., Johannsen A.D., Hermansen M.-L.F., Thomsen M.K., Erikstrup C., Hauge E.-M., et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol. Int. 2021;41:1925–1931. doi: 10.1007/s00296-021-04972-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04972-7</ArticleId><ArticleId IdType="pmc">PMC8412379</ArticleId><ArticleId IdType="pubmed">34476603</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveen R., Parodis I., Joshi M., Sen P., Lindblom J., Agarwal V., Lilleker J.B., Tan A.L., Nune A., Shinjo S.K., et al. COVID-19 vaccination in autoimmune diseases (COVAD) study: Vaccine safety and tolerance in rheumatoid arthritis. Rheumatology. 2023;62:2366–2376. doi: 10.1093/rheumatology/keac624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac624</ArticleId><ArticleId IdType="pubmed">36315075</ArticleId></ArticleIdList></Reference><Reference><Citation>Botwin G.J., Li D., Figueiredo J., Cheng S., Braun J., McGovern D.P.B., Melmed G.Y. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. Am. J. Gastroenterol. 2021;116:1746–1751. doi: 10.14309/ajg.0000000000001342.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001342</ArticleId><ArticleId IdType="pmc">PMC8484025</ArticleId><ArticleId IdType="pubmed">34047304</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino R., Pellino G., Selvaggi L., Selvaggi F., Federico A., Romano M., Gravina A.G. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: A monocentric real-life study. Expert. Rev. Clin. Pharmacol. 2022;15:1243–1252. doi: 10.1080/17512433.2022.2120466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2022.2120466</ArticleId><ArticleId IdType="pubmed">36047032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz V.A., Guimarães C., Rêgo J., Machado K.L.L.L., Miyamoto S.T., Burian A.P.N., Dias L.H., Pretti F.Z., Batista D.C.F.A., Mill J.G., et al. Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: Data from the Brazilian multicentric study SAFER. J. Rheumatol. 2024;64:58. doi: 10.1186/s42358-024-00397-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-024-00397-5</ArticleId><ArticleId IdType="pubmed">39135131</ArticleId></ArticleIdList></Reference><Reference><Citation>Isnardi C.A., Schneeberger E.E., Kreimer J.L., Luna P.C., Echeverría C., Roberts K., de la Vega M.C., Virasoro B.M., Landi M., Quintana R., et al. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: The SAR-CoVAC Registry-protocol and preliminary data. Clin. Rheumatol. 2022;41:3199–3209. doi: 10.1007/s10067-022-06253-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06253-5</ArticleId><ArticleId IdType="pmc">PMC9244362</ArticleId><ArticleId IdType="pubmed">35760939</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera J.A., Tamborska A.A., Doheim M.F., Garcia-Azorin D., Gezegen H., Guekht A., Khan Y.K.A., Santacatterina M., Sejvar J., Thakur K.T., et al. contributors from the Global COVID-19 Neuro Research Coalition. Neurological events reported after COVID-19 vaccines: An analysis of VAERS. Ann. Neurol. 2022;91:756–771. doi: 10.1002/ana.26339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26339</ArticleId><ArticleId IdType="pmc">PMC9082459</ArticleId><ArticleId IdType="pubmed">35233819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunjimi O.B., Tsalamandris G., Paladini A., Varrassi G., Zis P. Guillain-Barré syndrome induced by vaccination against COVID-19: A systematic review and meta-analysis. Cureus. 2023;15:e37578. doi: 10.7759/cureus.37578.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.37578</ArticleId><ArticleId IdType="pmc">PMC10183219</ArticleId><ArticleId IdType="pubmed">37193456</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada  Reported Side Effects Following COVID-19 Vaccination in Canada. 2024.  [(accessed on 3 September 2024)].  Available online:  https://health-infobase.canada.ca/covid-19/vaccine-safety/</Citation></Reference><Reference><Citation>Wong K.K., Heilig C.M., Hause A., Myers T.R., Olson C.K., Gee J., Marquez P., Strid P., Shay D.K. Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020-January, 2022: An observational cohort study. Lancet. Digit. Health. 2022;4:e667–e675. doi: 10.1016/S2589-7500(22)00125-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00125-X</ArticleId><ArticleId IdType="pmc">PMC9363036</ArticleId><ArticleId IdType="pubmed">35961858</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen B., Prasad V. COVID-19 vaccine induced myocarditis in young males: A systematic review. Eur. J. Clin. Investig. 2023;53:e13947. doi: 10.1111/eci.13947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13947</ArticleId><ArticleId IdType="pmc">PMC9880674</ArticleId><ArticleId IdType="pubmed">36576362</ArticleId></ArticleIdList></Reference><Reference><Citation>D’almeida S., Markovic S., Hermann P., Bracht H., Peifer J., Ettrich T.J., Imhof A., Zhou S., Weiss M., Viardot A., et al. Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated. Hum. Vaccines. Immunother. 2023;19:2252239. doi: 10.1080/21645515.2023.2252239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2252239</ArticleId><ArticleId IdType="pmc">PMC10478733</ArticleId><ArticleId IdType="pubmed">37655367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung M.W., Dayam R.M., Shapiro J.R., Law J.C., Chao G.Y.C., Pereira D., Goetgebuer R.L., Croitoru D., Stempak J.M., Acheampong L., et al. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. J. Immunol. 2023;211:351–364. doi: 10.4049/jimmunol.2300190.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2300190</ArticleId><ArticleId IdType="pmc">PMC10352588</ArticleId><ArticleId IdType="pubmed">37326480</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit J.M., Breznik J.A., Ang J.C., Bhakta H., Huynh A., Cowbrough B., Baker B., Heessels L., Lodhi S., Yan E., et al. Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis. Sci. Rep. 2023;13:22846. doi: 10.1038/s41598-023-50263-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-50263-5</ArticleId><ArticleId IdType="pmc">PMC10739702</ArticleId><ArticleId IdType="pubmed">38129594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>